Pylarify PSMA PET/CT Scan is a cutting-edge nuclear medicine that has been proven to be exceptionally sensitive for detecting prostate cancer using positron emission tomography (PET) imaging exams. It is a novel prostate cancer-specific imaging agent, referred to as a Prostate-Specific Membrane Antigen (PSMA), and has recently been approved by the Food and Drug Administration and the Centers for Medicare and Medicaid Services (CMS) for coverage.
PET scans use a radioactive dye to light up specific regions in the body. Pylarify targets Prostate-Specific Membrane Antigen (PSMA), a protein found on the surface of prostate cancer cells, and binds to it, enabling the PET scan to detect and locate the presence of prostate cancer cells.
Pylarify is indicated for positive lesions in men with prostate cancer, men with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level; men with a suspected metastasis are also candidates for initial definitive therapy. This exam is offered to our Medicare and self-pay patients only.
Our Mission includes providing world-class diagnostic imaging services leveraging the most innovative technology available to improve the health of our community. Pylarify PSMA-PET/CT Scans are the most sensitive scans available for the detection of prostate tumors. They can see small tumors where other types of scans could miss them. Therefore Pylarify PSMA PET/CT Scan is more accurate for finding or ruling out metastatic tumors at the time of diagnosis. Providing this cutting-edge diagnostic tool will assist our referring physicians with developing the best treatment plan possible for our shared patients.